Ginger J. Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ginger J. Tsai has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Brian H. Shirts
Department of Laboratory Medicine and Pathology, University of Washington
3 shared publications Deborah J. Bowen
Department of Bioethics and Humanities University of Washington Seattle WA USA
3 shared publicationsBrian H. Shirts
Department of Laboratory Medicine University of Washington Seattle WA USA
2 shared publicationsLauren Thomas Garrett
Department of Laboratory Medicine, University of Washington, Seattle, Washington
2 shared publicationsWylie Burke
Department of Bioethics and Humanities University of Washington Seattle WA USA
2 shared publications- Amanda Connors
Division of Maternal‐Fetal Medicine Lehigh Valley Health Network Allentown Pennsylvania USA
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in Prenatal Diagnosis
Prenatal Syndromic Presentation of Novel Biallelic ARFGEF1 Variants Involves Congenital Skeletal Defects, Growth Restriction, and Brain Anomalies
- 13 November 2026
- Published by Wiley in Prenatal Diagnosis
Open AccessPrenatal Syndromic Presentation of Novel Biallelic ARFGEF1 Variants Involves Congenital Skeletal Defects, Growth Restriction, and Brain Anomalies
- 9 January 2020
- Published by Wiley in Journal of Genetic Counseling
- Vol. 29 (5) , 857-866
Exploring relatives’ perceptions of participation, ethics, and communication in a patient‐driven study for hereditary cancer variant reclassification
Effective communication of genetic information within families depends on several factors. Few studies explore intra‐familial communication of variant of uncertain significance (VUS) results or active collaboration between family members to classify VUS. Our qualitative study aimed to describe the experiences of individuals asked by family members to participate in the FindMyVariant study, a patient‐driven family study which aimed to reclassify a clinically identified familial VUS in a hereditary cancer gene. We collected feedback from 56 individuals from 21 different families through phone interviews and written correspondence, transcribed the interviews, and performed thematic analysis on all text. We describe themes from three main topics: participation, ethical considerations, and study impacts. Participation in the FindMyVariant study, defined as returning a sample for targeted genotyping, was motivated by convenience and a desire to help the family, oneself, and science. Relatives were generally responsive to invitations to participate in FindMyVariant from another family member. Those who declined to participate did so due to concerns about research program confidentiality rather than family dynamics. No major ethical issues arose in response to the patient‐driven study structure, and no major changes in stress and anxiety, medical care, or behavior occurred. Participation in patient‐driven familial VUS classification studies has a neutral or positive impact on family health communication. While it is important to design studies to minimize familial coercion, intra‐familial confidentiality breaches, and misinterpretation of genetic results, these were not major concerns among relatives in this study. Clinicians and laboratories may consider encouraging familial communication about genetic variants using family members as liaisons.
- 9 January 2020
- Published by Wiley in Journal of Genetic Counseling
- Vol. 29 (5) , 857-866
Exploring relatives’ perceptions of participation, ethics, and communication in a patient‐driven study for hereditary cancer variant reclassification
Effective communication of genetic information within families depends on several factors. Few studies explore intra‐familial communication of variant of uncertain significance (VUS) results or active collaboration between family members to classify VUS. Our qualitative study aimed to describe the experiences of individuals asked by family members to participate in the FindMyVariant study, a patient‐driven family study which aimed to reclassify a clinically identified familial VUS in a hereditary cancer gene. We collected feedback from 56 individuals from 21 different families through phone interviews and written correspondence, transcribed the interviews, and performed thematic analysis on all text. We describe themes from three main topics: participation, ethical considerations, and study impacts. Participation in the FindMyVariant study, defined as returning a sample for targeted genotyping, was motivated by convenience and a desire to help the family, oneself, and science. Relatives were generally responsive to invitations to participate in FindMyVariant from another family member. Those who declined to participate did so due to concerns about research program confidentiality rather than family dynamics. No major ethical issues arose in response to the patient‐driven study structure, and no major changes in stress and anxiety, medical care, or behavior occurred. Participation in patient‐driven familial VUS classification studies has a neutral or positive impact on family health communication. While it is important to design studies to minimize familial coercion, intra‐familial confidentiality breaches, and misinterpretation of genetic results, these were not major concerns among relatives in this study. Clinicians and laboratories may consider encouraging familial communication about genetic variants using family members as liaisons.
- Open Access
- 1 September 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (9) , 1325-1331
Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers
The CDH1 gene (OMIM:192090) encodes the protein E-cadherin, a cell-to-cell adhesion molecule.1 Hereditary diffuse gastric cancer (HDGC) syndrome is caused by germline pathogenic variants in the CDH1 gene and is characterized by an increased risk for diffuse gastric cancer (DGC) and lobular breast cancer (LBC).2 Clinical testing criteria and medical management recommendations for HDGC were first established and published in 1999 by the International Gastric Cancer Linkage Consortium (IGCLC), a multidisciplinary collaboration of international clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists.3 Revisions to the initial criteria were subsequently published in 2010 and 2015 (Table 1).2,4 Recent evaluation of the revised 2015 IGCLC clinical testing criteria in a laboratory-based CDH1 pathogenic variant cohort found that 65% of all individuals with pathogenic variants did not meet criteria.5 In addition, it has been suggested that CDH1 pathogenic variants may be present in women presenting with lobular breast cancer and no family history of gastric cancer.6,7 International Gastric Cancer Linkage Consortium criteria were developed to define a clinical syndrome and facilitate identification of risk genes rather than to determine risk in all individuals with a genetically defined syndrome. These observations suggest that criteria for clinical HDGC and genetic CDH1 syndromes may need to be separated.
- 1 September 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (9) , 1325-1331
Open AccessComparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers
The CDH1 gene (OMIM:192090) encodes the protein E-cadherin, a cell-to-cell adhesion molecule.1 Hereditary diffuse gastric cancer (HDGC) syndrome is caused by germline pathogenic variants in the CDH1 gene and is characterized by an increased risk for diffuse gastric cancer (DGC) and lobular breast cancer (LBC).2 Clinical testing criteria and medical management recommendations for HDGC were first established and published in 1999 by the International Gastric Cancer Linkage Consortium (IGCLC), a multidisciplinary collaboration of international clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists.3 Revisions to the initial criteria were subsequently published in 2010 and 2015 (Table 1).2,4 Recent evaluation of the revised 2015 IGCLC clinical testing criteria in a laboratory-based CDH1 pathogenic variant cohort found that 65% of all individuals with pathogenic variants did not meet criteria.5 In addition, it has been suggested that CDH1 pathogenic variants may be present in women presenting with lobular breast cancer and no family history of gastric cancer.6,7 International Gastric Cancer Linkage Consortium criteria were developed to define a clinical syndrome and facilitate identification of risk genes rather than to determine risk in all individuals with a genetically defined syndrome. These observations suggest that criteria for clinical HDGC and genetic CDH1 syndromes may need to be separated.
- 11 July 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (12) , 1800-1807
Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees
Recent studies have reported novel cancer risk associations with incidentally tested genes on cancer risk panels using clinically ascertained cohorts. Clinically ascertained pedigrees may have unknown ascertainment biases for both patients and relatives. We used a method to assess gene and variant risk and ascertainment bias based on comparing the number of observed disease instances in a pedigree given the sex and ages of individuals with those expected given established population incidence. We assessed the performance characteristics of the method by simulating families with varying genetic risk and proportion of individuals genotyped. We implemented this method using SEER cancer incidence data to assess clinical ascertainment bias in a set of 42 pedigrees with clinical testing ordered for either breast/ovarian cancer or colorectal/endometrial cancer at the University of Washington and negative sequencing results. In addition to expected biases consistent with the stated testing purpose, there were trends suggesting increased colorectal and endometrial cancer in pedigrees tested for breast cancer risk and trends suggesting increased breast cancer in families tested for colon cancer risk. There was no observed selection bias for prostate cancer in this set of families. This analysis illustrates that clinically ascertained data sets may have subtle biases. In the future, researchers seeking to explore risk associations with clinical data sets could assess potential ascertainment bias by comparing incidence of disease in families that test negative under given ordering criteria to expected population disease frequencies. Failure to assess for ascertainment bias increases the risk of false genetic associations.
- 11 July 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (12) , 1800-1807
Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees
Recent studies have reported novel cancer risk associations with incidentally tested genes on cancer risk panels using clinically ascertained cohorts. Clinically ascertained pedigrees may have unknown ascertainment biases for both patients and relatives. We used a method to assess gene and variant risk and ascertainment bias based on comparing the number of observed disease instances in a pedigree given the sex and ages of individuals with those expected given established population incidence. We assessed the performance characteristics of the method by simulating families with varying genetic risk and proportion of individuals genotyped. We implemented this method using SEER cancer incidence data to assess clinical ascertainment bias in a set of 42 pedigrees with clinical testing ordered for either breast/ovarian cancer or colorectal/endometrial cancer at the University of Washington and negative sequencing results. In addition to expected biases consistent with the stated testing purpose, there were trends suggesting increased colorectal and endometrial cancer in pedigrees tested for breast cancer risk and trends suggesting increased breast cancer in families tested for colon cancer risk. There was no observed selection bias for prostate cancer in this set of families. This analysis illustrates that clinically ascertained data sets may have subtle biases. In the future, researchers seeking to explore risk associations with clinical data sets could assess potential ascertainment bias by comparing incidence of disease in families that test negative under given ordering criteria to expected population disease frequencies. Failure to assess for ascertainment bias increases the risk of false genetic associations.
- 31 December 2018
- Published by Wiley in Journal of Genetic Counseling
- Vol. 28 (3) , 558-569
Patient goals, motivations, and attitudes in a patient‐driven variant reclassification study
Family studies to reclassify clinically ascertained variants of uncertain significance (VUS) can impact risk assessment, medical management, and psychological outcomes for patients and their families. There are limited avenues for patients and their families to actively participate in VUS reclassification, and access to family studies at most commercial laboratories is restricted by multiple factors. To explore patient attitudes about participation in family studies for VUS reclassification, we conducted semistructured pre‐ and post‐participation telephone interviews with 38 participants in a family‐based VUS reclassification study that utilized a patient‐driven approach for family ascertainment and recruitment. Participants had VUS from multigene panel testing performed at multiple clinical laboratories for cancer or other disease risk. Inductive thematic analysis of transcribed interviews highlighted four major themes: (a) Participants’ study goals were driven by the desire to resolve uncertainty related to the VUS, (b) Participants had mixed reactions to the VUS reclassification outcomes of the study, (c) Personal, public, and familial knowledge increased through study participation and (d) Participants used study participation to actively cope with the uncertainty of a VUS. As personalized genomic medicine becomes more prevalent, clinicians, clinical laboratories, and researchers could consider creating more opportunities for active partnership with patients and families, who are motivated to contribute data to familial VUS studies.
- 31 December 2018
- Published by Wiley in Journal of Genetic Counseling
- Vol. 28 (3) , 558-569
Patient goals, motivations, and attitudes in a patient‐driven variant reclassification study
Family studies to reclassify clinically ascertained variants of uncertain significance (VUS) can impact risk assessment, medical management, and psychological outcomes for patients and their families. There are limited avenues for patients and their families to actively participate in VUS reclassification, and access to family studies at most commercial laboratories is restricted by multiple factors. To explore patient attitudes about participation in family studies for VUS reclassification, we conducted semistructured pre‐ and post‐participation telephone interviews with 38 participants in a family‐based VUS reclassification study that utilized a patient‐driven approach for family ascertainment and recruitment. Participants had VUS from multigene panel testing performed at multiple clinical laboratories for cancer or other disease risk. Inductive thematic analysis of transcribed interviews highlighted four major themes: (a) Participants’ study goals were driven by the desire to resolve uncertainty related to the VUS, (b) Participants had mixed reactions to the VUS reclassification outcomes of the study, (c) Personal, public, and familial knowledge increased through study participation and (d) Participants used study participation to actively cope with the uncertainty of a VUS. As personalized genomic medicine becomes more prevalent, clinicians, clinical laboratories, and researchers could consider creating more opportunities for active partnership with patients and families, who are motivated to contribute data to familial VUS studies.
- 30 October 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 21 (6) , 1435-1442
Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance
- 30 October 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 21 (6) , 1435-1442
Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance
- 2 March 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (5) , 1041-1058
Attitudes Towards Prenatal Genetic Counseling, Prenatal Genetic Testing, and Termination of Pregnancy among Southeast and East Asian Women in the United States
Recognizing the heterogeneity of the Asian population with regards to acculturation, education, health awareness, and cultural values is vital for tailoring culturally sensitive and appropriate care. Prior studies show that cultural values influence perceptions of genetics within Asian populations. The reputation of the family unit factors into decisions such as pregnancy termination and disclosure of family medical history, and the nondirective model of American genetic counseling may conflict with the historical Asian model of paternalistic health care. Previous studies also provide conflicting evidence regarding correlations between education, acculturation, age, and awareness and perceptions of genetic testing. The aims of this study were to describe attitudes towards prenatal genetics among Southeast and East Asian women living in the United States for varying amounts of time and to explore sociocultural factors influencing those attitudes. Twenty‐three Asian women who were members of Asian cultural organizations in the United States were interviewed via telephone about their attitudes towards prenatal genetic counseling, prenatal genetic testing, and termination of pregnancy. Responses were transcribed and coded for common themes using a thematic analysis approach. Four major themes emerged. In general, participants: (1) had diverse expectations for genetic counselors; (2) tended to weigh risks and benefits with regards to genetic testing decisions; (3) had mixed views on termination for lethal and non‐lethal genetic conditions; and (4) identified cultural factors which influenced testing and termination such as lack of available resources, societal shame and stigma, and family pressure. These findings may allow prenatal genetic counselors to gain a richer, more nuanced understanding of their Asian patients and to offer culturally tailored prenatal genetic counseling.
- 2 March 2017
- Published by Wiley in Journal of Genetic Counseling
- Vol. 26 (5) , 1041-1058
Attitudes Towards Prenatal Genetic Counseling, Prenatal Genetic Testing, and Termination of Pregnancy among Southeast and East Asian Women in the United States
Recognizing the heterogeneity of the Asian population with regards to acculturation, education, health awareness, and cultural values is vital for tailoring culturally sensitive and appropriate care. Prior studies show that cultural values influence perceptions of genetics within Asian populations. The reputation of the family unit factors into decisions such as pregnancy termination and disclosure of family medical history, and the nondirective model of American genetic counseling may conflict with the historical Asian model of paternalistic health care. Previous studies also provide conflicting evidence regarding correlations between education, acculturation, age, and awareness and perceptions of genetic testing. The aims of this study were to describe attitudes towards prenatal genetics among Southeast and East Asian women living in the United States for varying amounts of time and to explore sociocultural factors influencing those attitudes. Twenty‐three Asian women who were members of Asian cultural organizations in the United States were interviewed via telephone about their attitudes towards prenatal genetic counseling, prenatal genetic testing, and termination of pregnancy. Responses were transcribed and coded for common themes using a thematic analysis approach. Four major themes emerged. In general, participants: (1) had diverse expectations for genetic counselors; (2) tended to weigh risks and benefits with regards to genetic testing decisions; (3) had mixed views on termination for lethal and non‐lethal genetic conditions; and (4) identified cultural factors which influenced testing and termination such as lack of available resources, societal shame and stigma, and family pressure. These findings may allow prenatal genetic counselors to gain a richer, more nuanced understanding of their Asian patients and to offer culturally tailored prenatal genetic counseling.